If you have been reading about Photo-oxidation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Because this process removes/inactivates the lipid coating of a virus, viruses without any sort of lipid envelope will be unaffected. There is also no inactivation effect by the buffers used in this process.
Chloral hydrate is a geminal diol with the formula Cl3C−CH(OH)2. It was first used as a sedative and hypnotic in Germany in the 1870s. Over time it was replaced by safer and more effective alternatives but it remained in use in the United States until at least the 1970s. It sometimes finds usage as a laboratory chemical reagent and precursor. It is derived from chloral (trichloroacetaldehyde) by the addition of one equivalent of water.
After the Netherlands in World War II in 1945, Korvezee returned to Delft, initially serving as a curator and, from 1948, as a lecturer in theoretical chemistry. Although an expert in radioactivity, she had no role in the planning of the reactor center later built on the university's grounds. When the chair became vacant following Scheffer's retirement, Korvezee was passed over once more. In 1954, the Department of Chemical Technology created an extraordinary professorship for her in the emerging field of theoretical chemistry largely regarded as compensation for the chairs she had earlier missed. Her appointment on 14 April 1954, making her the first female professor at Delft, received extensive press coverage. As a full professor, however, she retained the salary of her former lectureship. As professor, Korvezee supervised doctoral and master's students and published more than forty scientific works before 1940, many co-authored with fellow female assistants. She was a member of the Association of Women with an Academic Education (VVAO), though she was never actively involved in the women's movement despite being widely regarded as a feminist figure.
Tetraloop-receptor interactions combine base-pairing and stacking interactions between the loop nucleotides of a tetraloop motif and a receptor motif located within an RNA duplex, creating a tertiary contact that stabilizes the global tertiary fold of an RNA molecule. Tetraloops are also possible structures in DNA duplexes. Stem-loops can vary greatly in size and sequence, but tetraloops of four nucleotides are very common and they usually belong to one of three categories, based on sequence. These three families are the CUYG, UNCG, and GNRA (see figure on the right) tetraloops. In each of these tetraloop families, the second and third nucleotides form a turn in the RNA strand and a base-pair between the first and fourth nucleotides stabilizes the stemloop structure. It has been determined, in general, that the stability of the tetraloop depends on the composition of bases within the loop and on the composition of this "closing base pair". The GNRA family of tetraloops is the most commonly observed within Tetraloop-receptor interactions. Additionally, the UMAC tetraloops are known to be alternative versions of the GNRA loops, both sharing similar backbone structures; despite the similarities, they differ in the possible long-range interactions they are capable of.
Sources: en.wikipedia.org
18 October 2016: Astellas completes a clinical trial for Type-2 diabetes mellitus in Japan prior to October 2016 7 September 2016: Astellas Pharma plans a phase III trial for Type-1 diabetes mellitus (Combination therapy) in Japan 1 August 2016: Phase III clinical trials in type 1 diabetes mellitus (combination therapy) in Japan Ipragliflozin was also in development for type 2 diabetes mellitus in the U.S., Europe and other countries, and three phase II trials were completed in combination with metformin. This was since discontinued.
=== Since 2014 === In early 2014, Marcel H. Van Herpen, director of the Cicero Foundation, published the book Putin's Wars: The Rise of Russia's New Imperialism that offered the first systematic analysis of the war in the wider historical context. Van Herpen suggested that although the official Russian narrative (that the war started with a Georgian "surprise" attack on Tskhinvali) became widely accepted, this was not true since the war's history actually began in 2000 (although Russia had planned to annex Abkhazia already in the 1990s), and 7–12 August 2008 was the third phase of the war. Illegal entry of the troops from Russia into South Ossetia before the Georgian military operation began on 7 August, was a casus belli. Because of the Russian propaganda, the victim (Georgia) became the aggressor. Van Herpen finished writing the book in late 2013, and predicted "if Ukraine were to opt for deeper integration into the European Union, a Georgia scenario could not be excluded, in which the Kremlin could provoke riots in Eastern Ukraine or the Crimea, where many Russian passport holders live". In April 2014, Jeffrey Mankoff argued that Russia and South Ossetia provoked the Georgian response. Mankoff also noted that while Russia used the justification of the defense of minorities in Georgia for military intervention, Russia never intervened in Central Asia to protect ethnic Russians there.
Dermatobia hominis (human botfly) Cordylobia anthropophaga (tumbu fly) Cordylobia rodhaini (Lund's fly) Oestrus ovis (sheep botfly) Hypoderma spp. (cattle botflies or ox warbles) Gasterophilus spp. (horse botfly) Cochliomyia hominivorax (new world screwworm fly) Chrysomya bezziana (old world screwworm fly) Auchmeromyia senegalensis (Congo floor maggot) Cuterebra spp. (rodent and rabbit botfly)
Sources: en.wikipedia.org
Insulin therapy can be injection under the skin multiple times a day, or can be delivered continuously as a basal amount with boluses for high blood sugar or before meals using an insulin pump. A diabetic diet, exercise, and lifestyle modifications are considered cornerstones of management. If left untreated, type 1 diabetes results in death. Type 1 diabetes can cause many complications if blood sugar control is not very well controlled. Complications of relatively rapid onset include diabetic ketoacidosis and nonketotic hyperosmolar coma. Long-term complications include heart disease, stroke, kidney failure (Diabetic Nephropathy), foot ulcers, and damage to the eyes (diabetic retinopathy). As insulin lowers blood sugar levels, complications may arise from low blood sugar if more insulin is taken than necessary. Type 1 diabetes makes up an estimated 5–10% of all diabetes cases. The number of people affected globally is unknown, although it is estimated that about 80,000 children develop the disease each year. Within the United States the number of people affected is estimated to be one to three million. Rates of disease vary widely, with approximately one new case per 100,000 per year in East Asia and Latin America and around 30 new cases per 100,000 per year in Scandinavia and Kuwait. It typically begins in children and young adults but can begin at any age.
Gonadotropin-releasing hormone (GnRH) is a releasing hormone responsible for the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary. GnRH is a tropic peptide hormone synthesized and released from GnRH neurons within the hypothalamus. GnRH is inhibited by testosterone. The peptide belongs to gonadotropin-releasing hormone family. It constitutes the initial step in the activation of hypothalamic–pituitary–gonadal axis. While there are related hormones which are called Gonadotropin-releasing hormones, (GnRH2 and GnRH3), GnRH1 is the form of gonadotropin-releasing hormone that is involved in pituitary gland signaling in humans. Because of this, it is often referred to as just GnRH in this context.
Bupropion has a particularly odd pattern of inducing DAT inhibition, since it displays markedly enhanced binding affinity towards the DAT-(NET S1) mutant (DAT with NET primary binding site) over normal (wild-type) DAT, and noticeably diminished binding affinity towards the NET-(DAT S1) mutant (NET with DAT primary binding site) over regular (wild-type) NET. In spite of clear preference for NET binding site by itself, bupropion retains overall preference for complete DAT, implying that bupropion may make use of non-binding sites on the DAT molecule to exert its own binding, as well as the potential of augmented affinity for NET if its binding site is otherwise conformationally exposed. Bupropion has been claimed to be a sigma σ1 receptor agonist. Its antidepressant-like effects in rodents depend on σ1 receptor activation. They are enhanced and inhibited by σ1 receptor agonists and antagonists, respectively. However, no data on the binding or functional effects of bupropion at the human sigma receptors seem to be available. In any case, bupropion has been reported to bind to rodent σ1 receptors with IC50Tooltip half-maximal inhibitory concentration values of 580 to 2,100 nM. In contrast to many other phenethylamines and amphetamines, bupropion is not an agonist of the trace amine-associated receptor 1 (TAAR1). Bupropion has been found to have a mixture of anti-inflammatory and pro-inflammatory activity through modulation of the immune system. One such mechanism underlying these effects may be reduced levels of the pro-inflammatory cytokine tumor necrosis factor alpha (TNFα).
== History == Prosenjit Choudhury was, at the time, a culinary expert at Sayaji Hotels. While working at the hotel, he introduced the concept of live grills similar to Korean barbecue in order to enhance the buffet experience to avoid cold appetisers. This idea proved to be popular and with the support of Sajid Dhanani, the managing director of Sayaji Hotels, Choudhury established the first outlet at Pali Hill in Mumbai, India in 2006. The brand had expanded to cities such as New Delhi and Bengaluru by 2008. After Sajid Dhanani's death in 2012, his brother Kayum Dhanani took over the business. The company opened its 100th outlet in 2018. The company offered its IPO in 2021. The IPO raised ₹453 crore (US$52 million), with ₹180 crore as fresh capital for expansion and debt repayment, and ₹273 crore as an offer for sale by existing investors. The stock was reported to perform poorly, due to factors such as the COVID-19 pandemic's impact on the restaurant market, weakening sales and increased competition. An Indian Express article highlighted how the buffet business was stalling due to new customer trends, affecting the growth of Barbeque Nation. As of 2022, the company owns an 86.57% stake in Red Apple Kitchen Consultancy Private Limited, which manages an Italian restaurant chain, Toscano.
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.